VolitionRX Ltd (AMEX:VNRX)

$ 0.62 0 (0%) Market Cap: 51.42 Mil Enterprise Value: 45.19 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 38/100

Q1 2024 VolitionRX Ltd Earnings Call Transcript
May 14, 2024

$0.75 (-14.53%)

Earnings
Q4 2023 VolitionRX Ltd Earnings Call Transcript
Mar 26, 2024

$0.7498 (+4.14%)

Earnings
VolitionRX Ltd Data Insights Webinar Transcript
Oct 26, 2023
VolitionRX Ltd at LD Micro Main Event XVI Conference Transcript
Oct 04, 2023
Q2 2023 VolitionRX Ltd Earnings Call Transcript
Aug 15, 2023

$1.21 (-1.63%)

Earnings
VolitionRX Ltd Capital Market Day Transcript
May 11, 2023
Q1 2023 VolitionRX Ltd Earnings Call Transcript
May 11, 2023

$1.89 (-1.05%)

Earnings
Q4 2022 VolitionRX Ltd Earnings Call Transcript
Mar 16, 2023

$1.72 (+11.69%)

Earnings
VolitionRX Ltd at OTC Markets Life Science Investor Forum (Virtual) Transcript
Mar 09, 2023
VolitionRX Ltd at Sidoti & Company January Micro-Cap Virtual Conference Transcript
Jan 19, 2023
VolitionRX Ltd at Issuer Direct Planet MicroCap Showcase (Virtual) Transcript
Dec 07, 2022
Q3 2022 VolitionRX Ltd Earnings Call Transcript
Nov 15, 2022

$1.76 (+6.02%)

Earnings
VolitionRX Ltd at OTC Markets Life Sciences Investor Forum Transcript
Sep 15, 2022
Q2 2022 VolitionRX Ltd Earnings Call Transcript
Aug 11, 2022

$2.02

Earnings
Q1 2022 VolitionRX Ltd Earnings Call Transcript
May 12, 2022

$2.11 (-9.83%)

Earnings
Q4 2021 VolitionRX Ltd Earnings Call Transcript
Mar 31, 2022

$3.01 (-7.10%)

Earnings
Q3 2021 VolitionRX Ltd Earnings Call Transcript
Nov 11, 2021

$3.68 (+2.22%)

Earnings
VolitionRX Ltd at SNN Network Summer Event (Virtual) Transcript
Aug 18, 2021
Q2 2021 VolitionRX Ltd Earnings and Business Update Call Transcript
Aug 12, 2021
Q1 2021 VolitionRX Ltd Earnings Call Transcript
May 12, 2021

$3.16 (+0.96%)

Earnings
Q3 2020 VolitionRX Ltd Earnings Call Transcript
Nov 13, 2020

$3.46 (+7.45%)

Earnings
VolitionRx Limited Presentation at the Rocky Mountain Microcap Conference VI Transcript
Nov 13, 2020
VolitionRX Ltd To Provide Corporate Update Transcript
Oct 14, 2020
VolitionRX Ltd To Present At GCFF Transcript
Sep 10, 2020
VolitionRX Ltd At SNN Network Transcript
Aug 19, 2020
Q1 2020 VolitionRX Ltd Earnings Call Transcript
May 08, 2020

$4.16 (-0.72%)

Earnings
VolitionRx Ltd. Webcast SNN Network Transcript
Apr 29, 2020
Q4 2019 VolitionRX Ltd Earnings Call Transcript
Feb 21, 2020

$4.57 (-8.23%)

Earnings
Q3 2019 VolitionRX Ltd Earnings Call Transcript
Nov 13, 2019

$5.36 (+3.28%)

Earnings

VolitionRx Ltd. Webcast SNN Network Transcript

Apr 29, 2020 / NTS GMT

Release Date Price: $4.31 (+3.36%)

Transcript 10-Q8-K

Operator

Greetings, and welcome to the VolitionRx webcast. It is now my pleasure to introduce your host, Scott Powell, Head of Investor Relations and US CFO. Thank you, Mr. Powell. You may begin.

Scott Powell

VolitionRx Ltd - EVP, IR & CFO, Volition America, Inc.

Thank you, Doug, and welcome, everyone, to the VolitionRx Limited investor presentation. I hope you're all doing well in these different and challenging times. Thank you very much for joining me today to hear a bit more about the Volition story, and, for those of you who are familiar, to get an update on some of our current developments and upcoming milestones throughout the course of 2020 and 2021. So again, we're VolitionRx Limited, ticker VNRX on the NYSE American stock Exchange.

And I'd point you to this slide. I will be making some forward-looking statements during this presentation. This slide, easy to read. Our mission is simple: we want to save lives. What is Volition doing? We are a diagnostics company. We're developing blood tests primarily to screen for different cancer types. And I'll

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.